<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644968</url>
  </required_header>
  <id_info>
    <org_study_id>03-066A</org_study_id>
    <nct_id>NCT01644968</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer</brief_title>
  <official_title>Phase 1 Trial of a Monoclonal Antibody to OX40 in Patients With Advanced Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the safety and highest tolerated dose of anti-OX40 in
      patients with advanced cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and determine the maximal tolerated dose of anti-OX40;
      evaluated the immune response to the study treatment; measure the pharmacokinetics of
      anti-OX40; monitor tumor regression, and identify the most biologically active dose of
      anti-OX40 to induce antigen-specific responses to a variety of immunogens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2003</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>28 Days</time_frame>
    <description>A dose limiting toxicity is defined as any grade &gt;=3 hematologic (except lymphopenia) or non-hematologic toxicity (except hypothyroidism or vitiligo) that, in the opinion of the investigator is considered at lease possibly related to the study treatment. If DLT is observed in greater than two patient in any cohort, then the previous cohort will be the maximal tolerated dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Pre-study, Days 5, 8, 15, 29, 36, 43, and 57.</time_frame>
    <description>Blood tests and leukapheresis product will be collected to determine the response to three types of reporter antigens: (1) new antigen (keyhole limpet hemocyanin (KLH)), (2) recall protein antigen (tetanus), and (3) viral antigen (cytomegalovirus (CMV)). Changes in the number of antigens will be used to determine immune response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>KLH + anti-OX40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetanus vaccine + anti-OX40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 1 anti-OX40</intervention_name>
    <description>0.1 mg/kg anti-OX40 on days 1, 3, and 5</description>
    <arm_group_label>KLH + anti-OX40</arm_group_label>
    <arm_group_label>Tetanus vaccine + anti-OX40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 2 anti-OX40</intervention_name>
    <description>.4 mg/kg anti-OX40 on days 1, 3, and 5</description>
    <arm_group_label>KLH + anti-OX40</arm_group_label>
    <arm_group_label>Tetanus vaccine + anti-OX40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cohort 3 anti-OX40</intervention_name>
    <description>2.0 mg/kg anti-OX40 on days 1, 3, and 5</description>
    <arm_group_label>KLH + anti-OX40</arm_group_label>
    <arm_group_label>Tetanus vaccine + anti-OX40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus Day 29</intervention_name>
    <description>Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29</description>
    <arm_group_label>KLH + anti-OX40</arm_group_label>
    <other_name>Tetanus Toxoid, Tetanus Toxoid Adsorbed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus Day 1</intervention_name>
    <description>Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.</description>
    <arm_group_label>Tetanus vaccine + anti-OX40</arm_group_label>
    <other_name>Tetansu Toxoid, Tetanus Toxoid Adsorbed.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH Day 1</intervention_name>
    <description>1 mg KLH in 1 cc diluent subcutaneously on Day 1.</description>
    <arm_group_label>KLH + anti-OX40</arm_group_label>
    <other_name>Immucothel.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH Day 29</intervention_name>
    <description>1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.</description>
    <arm_group_label>Tetanus vaccine + anti-OX40</arm_group_label>
    <other_name>Immucothel.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with uncurable metastatic carcinoma, lymphoma, or sarcoma.

          -  ECOG performance status 0, 1, 2

          -  No active bleeding

          -  No clinical coagulopathy

          -  Anticipated lifespan greater than 12 weeks

        Exclusion Criteria:

          -  Active residual toxicity from prior therapies

          -  Active Infection

          -  HIV positive

          -  Hepatitis B or C positive

          -  Pregnant or nursing women

          -  Requirement for oral steroids

          -  Brain metastases

          -  Presence or history of autoimmune disease

          -  Shellfish or tetanus allergy

          -  Splenomegaly

          -  Lymph nodes greater than 10 cm in maximal diameter

          -  Uncontrolled angina or class II or IV heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic carcinoma</keyword>
  <keyword>lymphoma</keyword>
  <keyword>sarcoma</keyword>
  <keyword>anti-OX40</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

